Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Raymond

Showing results (121-130 of 173) with videos related to

Pageof 18
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 9, 2010
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignanciesChristophe Le Tourneau, Sandrine Faivre, Valérie Laurence, et al.
Molecular Cancer Therapeutics|April 22, 2010
Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cellsMaria Serova, Lucile Astorgues-Xerri, Ivan Bieche, et al.
British Journal of Cancer|November 22, 2017
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined responseAngela Lamarca, Jorge Barriuso, Matthew Kulke, et al.
European Journal of Cancer (Oxford, England : 1990)|July 22, 2014
OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesisLucile Astorgues-Xerri, Maria E Riveiro, Annemilaï Tijeras-Raballand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2005
Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignanciesSandrine Faivre, Stéphanie Chièze, Catherine Delbaldo, et al.
Targeted Oncology|December 8, 2016
Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III TrialAaron Vinik, Andrew Bottomley, Beata Korytowsky, et al.
Histopathology|March 27, 2015
High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosisCindy Neuzillet, Anne Couvelard, Annemilaï Tijeras-Raballand, et al.
International Journal of Cancer|May 15, 2018
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancerEric Van Cutsem, Manuel Hidalgo, Jean-Luc Canon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
Characterization and multiparameter analysis of visual adverse events in irofulven single-agent phase I and II trialsEric Raymond, Carmen Kahatt, Marie Hélène Rigolet, et al.
Cancer Research|May 7, 2009
Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cellsAïda Ghoul, Maria Serova, Lucile Astorgues-Xerri, et al.
Pageof 18

Showing results (121-130 of 173) with videos related to

Sort By:
Pageof 18
European Journal of Cancer (Oxford, England : 1990)|September 9, 2010
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignanciesChristophe Le Tourneau, Sandrine Faivre, Valérie Laurence, et al.
Molecular Cancer Therapeutics|April 22, 2010
Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cellsMaria Serova, Lucile Astorgues-Xerri, Ivan Bieche, et al.
British Journal of Cancer|November 22, 2017
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined responseAngela Lamarca, Jorge Barriuso, Matthew Kulke, et al.
European Journal of Cancer (Oxford, England : 1990)|July 22, 2014
OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesisLucile Astorgues-Xerri, Maria E Riveiro, Annemilaï Tijeras-Raballand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2005
Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignanciesSandrine Faivre, Stéphanie Chièze, Catherine Delbaldo, et al.
Targeted Oncology|December 8, 2016
Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III TrialAaron Vinik, Andrew Bottomley, Beata Korytowsky, et al.
Histopathology|March 27, 2015
High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosisCindy Neuzillet, Anne Couvelard, Annemilaï Tijeras-Raballand, et al.
International Journal of Cancer|May 15, 2018
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancerEric Van Cutsem, Manuel Hidalgo, Jean-Luc Canon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
Characterization and multiparameter analysis of visual adverse events in irofulven single-agent phase I and II trialsEric Raymond, Carmen Kahatt, Marie Hélène Rigolet, et al.
Cancer Research|May 7, 2009
Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cellsAïda Ghoul, Maria Serova, Lucile Astorgues-Xerri, et al.
Pageof 18